Clinical trials: Leukemia, Acute Myeloid (AML)
Leukemia, Nonlymphocytic, Acute
AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years
AML2003 is a prospective randomized trial, to investigate the value of early allogeneic stem cell transplantation in aplasia after induction therapy for high risk patients with acute myeloid leukemia.
- Trial name
- NCT00180102
- Testing
- Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone, early allogeneic PBSCT within induction therapy, autologous PBSCT
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Technische Universität Dresden
Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission
This phase II trial studies how well donor cellular therapy after cytarabine works in treating patients with intermediate-risk acute myeloid leukemia with a decrease in or disappearance of signs and symptoms of cancer.
- Trial name
- NCT02587871
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Sponsor
- University of Southern California
Acute Myeloid Leukemia
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
This is a non-therapeutic study. Pediatric AML patients undergoing HCT with a myeloablative preparative regimen may be enrolled. Subjects can be enrolled 10-40 days prior to HCT.
- Trial name
- NCT01385787
- Where
- 38 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Leukemia
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01500499
- Testing
- gene expression analysis, gene rearrangement analysis, polymerase chain reaction
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia
Despite substantial progress in the treatment pediatric acute leukemia a significant number of children will experience primary or secondary resistance to the treatment.
- Trial name
- NCT01025778
- Testing
- Clofarabine for remission induction, Etoposide for remission induction, Cyclophosphamide for remission induction
- Where
- Sweden
- Volunteers
- 7 people
- Sponsor
- Lund University Hospital
Acute Myeloid Leukemia
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
The primary purpose of this study was to test the hypothesis that preemptive treatment with sabatolimab, alone or in combination with azacitidine, when administered to participants with Acute myeloid leukemia (AML)/secondary AML…
- Trial name
- NCT04623216
- Testing
- Sabatolimab, Azacitidine
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them, without harming normal cells.
- Trial name
- NCT00002609
- Testing
- lintuzumab, cytarabine, idarubicin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myeloid, Acute
A Long-term Follow-up Study of Patients Who Received VOR33
VOR33 long-term follow-up (LTFU) study
- Trial name
- NCT05309733
- Testing
- VOR33
- Where
- 11 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- Vor Biopharma
AML
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
In this open-label, randomized, prospective clinical trial, nucleophosmin-1(NPM1) mutated acute myeloid leukemia (AML) patients who have reached CR are randomized into two groups.The control group receive high-dose…
- Trial name
- NCT03031249
- Testing
- Cytarabine, all-trans retinoic acid, Arsenic Trioxide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn about the safety and tolerability of 3 different doses of CD33-CAR-T…
- Trial name
- NCT03126864
- Testing
- Leukapheresis, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study.
Newly diagnosed adults patients with Acute Myeloid Leukemia will be assessed as traditionally by the treating institution using classic clinical, demographic and cytogenetic variables.
- Trial name
- NCT04311060
- Testing
- Molecular panel
- Where
- 10 sites in Mexico
- Volunteers
- 100 people
- Sponsor
- Mexican Agrupation for Hematology Study
Cardiotoxicity, Acute Myeloid Leukemia in Children
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
Prevention and early detection of chemotherapy-induced cardiotoxicity in children with bone tumors and Acute Myeloid Leukemia by giving capoten
- Conditions
- Cardiotoxicity, Acute Myeloid Leukemia in Children, Bone Tumor
- Trial name
- NCT03389724
- Testing
- Capoten®
- Where
- Egypt
- Volunteers
- 245 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse
Yoga Fatigue Study
Fatigue is a major problem in children, adolescents and adults receiving intensive chemotherapy for cancer and in patients undergoing hematopoietic stem cell transplantation (HSCT).
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse, Burkitt's Lymphoma Stage III, Burkitt's Lymphoma Stage IV
- Trial name
- NCT02134782
- Testing
- Individualized Yoga Intervention Group, iPad Activity Control Group
- Where
- 3 sites in United States, Canada
- Volunteers
- 125 people
- Sponsor
- The Hospital for Sick Children
Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm
- Trial name
- NCT01445080
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
- Where
- 25 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Relapsed Acute Myeloid Leukaemia
Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation
In this phase 1 clinical trial, the investigators are testing an experimental medicine in children aged 6 months up to 16 years with acute myeloid leukaemia (AML), which has come back (relapsed).
- Trial name
- CARAML (NCT05942599)
- Testing
- Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Leukemia, Myelogenous, Acute
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
This is a phase II therapeutic study of related donor HLA-haploidentical NK-cell based therapy after a high dose of fludarabine/cyclophosphamide with denileukin diftitox preparative regimen for the treatment of poor prognosis…
- Trial name
- NCT01106950
- Testing
- Natural Killer Cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia
HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk
Patients with de novo AML enrolled in the study. Patient who has a HLA-identical donor is assigned to receive NST therapy with GVHD prophylaxis and who has no HLA-identical donor is assigned to receive MST therapy without GVHD…
- Trial name
- NCT02461121
- Testing
- HLA mismatched stem cell, HLA matched stem cell, cyclosporine A
- Where
- China
- Volunteers
- 156 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Leukemia
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer.
- Trial name
- NCT00897182
- Testing
- microarray analysis, polymerase chain reaction
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.